

## State of Oklahoma SoonerCare





## Padcev® (Enfortumab Vedotin-ejfv) Prior Authorization Form

Member Name:	Date of Birth:_	Member ID#:
Drug Information		
Physician billing (HCPCS code:	) 🗌	□Pharmacy billing (NDC:
Dose: Regimen:		Start Date (or date of next dose):
Billing Provider Information		
Provider NPI: Provider Name:		
Provider Phone: Provider Fax:		
Prescriber Information		
Prescriber NPI: Prescriber Name:		
Prescriber Phone:	Prescriber Fax:	Specialty:
<b>Criteria</b>		
For Initial Authorization:		
<ol> <li>Please indicate the diagnosis and information:</li></ol>		
For Continued Authorization:		
<ol> <li>Date of last dose:</li> <li>Does member have any evidence of progressive disease while on enfortumab vedotin therapy?</li> <li>Yes No</li> </ol>		
3. Has member experienced any adverse drug reactions related to enfortumab vedotin therapy?  Yes No		
If yes, please specify adverse reactions:  Additional Information:		
	is medically necessar	ry and all information is true and correct to the

Fax completed prior authorization request form to 888-601-8461 or submit Electronic Prior Authorization through CoverMyMeds® or SureScripts. All requested data must be provided. Incomplete forms or forms without the chart notes will be returned. Pharmacy Coverage Guidelines are available at AetnaBetterHealth.com/Oklahoma.

## CONFIDENTIALITY NOTICE

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.

Pharm - 145 7/24/2023